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ORIGINAL ARTICLE
Update of predictions of mortality from pleural
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Aims: To predict the expected number of pleural mesothelioma deaths in the Netherlands from 2000
to 2028 and to study the effect of main uncertainties in the modelling technique.
Methods: Through an age-period-cohort modelling technique, age specific mortality rates and cohort
relative risks by year of birth were calculated from the mortality of pleural mesothelioma in 1969–98.
Numbers of death for both sexes were predicted for 2000 to 2028, taking into account the most likely
demographic development. In a sensitivity analysis the relative deviation of the future death toll and
peak death number were studied under different birth cohort risk assumptions.
Results: The age-cohort model on mortality 1969–98 among men showed the highest age specific
death rates in the oldest age group (79 per 100 000 person-years in the age group 80–84 years) and
the highest relative risks for the birth cohorts of 1938–42 and 1943–47. Among men a small period
effect was observed. The age-cohort model was considered the best model for predicting future mor-
tality. The most plausible scenario predicts an increase in pleural mesothelioma mortality up to 490
cases per year in men, with a total death toll close to 12 400 cases during 2000–28. However, using
different assumptions this death toll could rise to nearly 15 000 in men (20% increase). Mortality
among women remains low, with a total death toll of about 800 cases. It is predicted that the total
death toll in the period 2000–28 is 44% lower than previous predictions using mortality data from
1969 to 1993.
Conclusion: Adding five recent years of observed mortality in an age-cohort model resulted in a 44%
lower prediction of the future death toll of pleural mesothelioma. A statistically significant period effect
was observed, possibly influenced by initial asbestos safety guidelines in the 1970s and introduction
of the ICD-10 codification.
In 1960 Wagner et al reported the first conclusive associationbetween asbestos exposure and pleural mesothelioma.1 2Mesothelioma affects mainly older men who in their youth
were exposed to asbestos in the workplace. Its incidence in
industrialised countries is about 5–50/million/year (male to
female ratio between 5:1 and 11:1). The average latency period
between first exposure to asbestos and diagnosis is 30 to 40
years, but shorter as well as longer latency periods have been
observed; the longest latency periods were reported among
women with possible household exposure.2–4 Since the 1960s,
mesothelioma has gained interest worldwide as a result of its
increasing incidence, its ominous prognosis, and medicolegal
issues.5
During the 1990s, forecastings of mesothelioma mortality
in several developed countries were made based on mortality
data before 1995.6–11 They estimated a rise in fatal cases until
2010–20, after which a fast decline is expected because of
asbestos bans. These projections used generalised linear mod-
els to calculate future deaths and to explain separate effects of
age, year of birth (that is, cohort effect), and/or year of death
(that is, period effect). For the Netherlands an increase from
300 pleural mesothelioma deaths in 1995 to approximately
960 around 2025 was predicted, with a fast decline after
2030.6 A similar projection for Western European countries for
the period 1995–2029 suggested an increase in the Nether-
lands to around 950 cases in the period 2020–25.9 Since results
of these analyses are sensitive to small changes in age specific
mortality and birth cohort risks, it was expected that the
inclusion of most recent mortality data may change previous
predictions. The first preventive measures on asbestos use in
the Netherlands were introduced in the mid-1970s.12 13 Hence,
it is of interest to evaluate whether the inclusion of data from
1994 to 1998 has a perceivable influence on the pleural
mesothelioma mortality.
The objective of this paper is to predict the expected number
of deaths from 2000 to 2028 and to conduct a sensitivity
analysis in order to study the influence of changes in model
assumptions on the prediction.
METHODS
Subjects
Statistics Netherlands (CBS) provided the latest mortality fig-
ures of pleural cancer and mesothelioma between 1969 and
1998, yearly age distributions of the Dutch population from
1949 to 1998, and estimations of Dutch population growth
from 2000 to 2030. Standard extrapolation demographic tech-
niques were applied for the latter figures. The Netherlands
Cancer Registry provided the morbidity figures of pleural
mesothelioma between 1989 and 1997. Pleural cancer was
defined using the International Classification of Diseases and
Related Health Problems (ICD). For the period 1969–78, ICD-8
163.0 pleural cancer was used, for 1979–95, ICD-9 163 pleural
cancer, and from 1996 onwards, pleural mesothelioma as
ICD-10 C450.We assumed cases of pleural cancer to be pleural
mesothelioma on a ratio 1:1 for the time span 1979–95. In
some countries it has been shown that a substantial
porportion of deaths coded 163 are not pleural mesothelioma
and a correction factor was applied for predictions in Western
Europe.7 9 14 However, because in the Dutch Cancer Registry
80–90% of all diagnoses were histologically confirmed, and the
total numbers in the Cancer Registry and the Mortality Regis-
try did correspond very well, it is assumed that overestimation
of pleural mesothelioma cases by using the pleural cancer
numbers will be very small.15 In the Netherlands, the
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non-mesothelioma pleural cancers in the Cancer Registry over
the period 1989–98 were less than 10% of all pleural
cancers.15 From 1996 to 1998, because of changes in the coding
system at the Mortality Registry, the majority of mesothe-
lioma deaths were registered as C459 (unspecified mesothe-
lioma). We estimated the number of pleural mesothelioma
deaths from 1996 to 1998 by the total number of mesothe-
lioma deaths (C45) minus the estimated number of non-
pleural mesothelioma deaths. The estimated number of
non-pleural mesothelioma cases was derived from available
information from the Netherlands Cancer Registry over the
period 1989–1997 (18.5 for men, 20 for women).15
In the analysis, deaths in people younger than 25 or older
than 85 years were not considered because they are very rare,
and imprecision in the diagnosis among the elderly has been
reported.16 Male and female mortality were separated, because
of the occupational nature of the disease and the historically
very low participation of women in the industrial workforce in
the Netherlands.12
Statistical analysis
All analyses were performed using Generalised Interactive
Linear Models (GLIM), version 4.09.17 Data were tabulated
into 12 five-year age groups (25–29 to 80–84 years old), 6 five-
year periods (1969–73 to 1994–98), and 15 five-year birth
cohort groups (1885 to 1955), identified by mid-point year
(that is, the birth cohort 1945 comprised those born from 1943
to 1947). Since mortality from pleural mesothelioma under
the age of 40 years was very rare, the 1953–57 birth cohort was
the youngest cohort for which an risk estimate could be
obtained. In order to calculate the number of person-years at
risk, interpolation was used to estimate the relative contribu-
tion of adjacent birth cohorts to the death rate in a particular
year and age group.
We calculated age specific mortality rates per 100 000
person-years and relative risks by birth cohort and period. We
used an age-period-cohort modelling technique, with the
assumption that the number of cases follows a Poisson distri-
bution, being the logarithm of death rates an additive function
of the parameters.18–21 The birth cohort of 1943–47 was
assigned the value 1. Fitting was done using an intercept only
model, a one-factor (age, period, or cohort) model, a
two-factor model (age-cohort, age-period, or cohort-period),
and a three-factor model. This last model used period as a
continuous variable or two periods with cut off 1996.
Individual parameters and their confidence intervals were
estimated by the maximum likelihood method (scaled
deviances). Changes in scaled deviances between models were
evaluated by the Pearson’s χ2 test and p values were calculated.
In order to predict the expected number of pleural mesothe-
lioma deaths in the period 2000 to 2028, the age specific rates
per birth cohort were multiplied by the projected age specific
survival in the Dutch population up to 2028.
Sensitivity analysis
In the sensitivity analysis four models were evaluated with
differences in available data on mortality from pleural
mesothelioma, statistical modelling, and assigned birth cohort
risks (see table 1). Model 1 was an age-cohort model derived
from available mortality data 1969–93. It included the
assumption that the risks of birth cohorts after 1958 sharply
decline with assigned risk of 0.44, 0.20, and 0 to the birth
cohorts 1958–62, 1963–67, and 1968–72, respectively. This
“old”model has been published previously.6 Model 1 compares
well to previous predictions on pleural mesothelioma mor-
tality in Europe which have also been based on available mor-
tality data 1969–93.9 10 Models 2 to 4 all used available
mortality data 1969–98, thus, including an additional five
years of observedmortality from pleural mesothelioma.Model
2 was an age-cohort model, but without any assumption on
changes in cohort specific risks of men born after 1957.Hence,
men born after 1957 were assigned a similar risk as birth
cohort 1953–57. Model 3 was also an age-cohort model with
the assumption that the risk of birth cohort 1958–62 was 50%
of the risk of the previous birth cohort. Birth cohorts beyond
1962 were assumed to have zero risk. This hypothesis was
based on the dramatic decrease in asbestos use. In the Nether-
lands asbestos use after 1984 was very small and an asbestos
ban was implemented in 1993.6 13 This “prior knowledge” was
used in the most plausible assumption on future mortality
prediction. Model 4 was an age-period-cohort model, intro-
ducing a period effect to model 3, reflecting the introduction of
ICD-10 in 1996.
The sensitivity in predictions was evaluated for peak num-
bers of deaths and total death toll. Model 3, regarded as the
most plausible model, was used as reference against all other
models. In addition, this model was chosen to present details
on age specific mortality rates and birth cohort risks.
RESULTS
During 1969–98, 5526 people in the Netherlands died as a
result of pleural mesothelioma (ratio male to female 6.5:1).
The mortality in men increased from 65 cases in 1969 to 265
cases in 1998. The death rate rose from 1.0 per 100 000 in 1969
to 3.9 per 100 000 in 1993, remaining more or less stable since
then. For women, the number of cases showed an irregular
pattern, reaching a peak of 43 deaths in 1994 and a
subsequent sharp decline to 19 cases in 1998. The death rate
among women fell from 0.4 per 100 000 in 1969 to 0.25 per
100 000 in 1998. The highest number of cases in men occurred
in the age group 65–69 years (800 cases) and for women in the
age group 70–74 years (125 cases).
Figures 1 and 2 describe the incidence of deaths from pleu-
ral mesothelioma among men and women by age group and
five-year period. The mortality rates among persons of 45
years or younger are not depicted since these were close to
zero. In each period the incidence of deaths from pleural mes-
othelioma increased strongly with age. Among men the 50–54
year age specific rate was 14 per 100 000 person-years and the
70–74 year age specific rate was 143 per 100 000 person-years.
Among women these rates were 0.8 and 5 per 100 000 person-
years, respectively. There was an increase over time in the age
specific mortality rates for both men and women in the age
Table 1 Four models with differences in available data on mortality from pleural mesothelioma, statistical modelling,
and assigned birth cohort risks to be used in predictions of number of deaths from pleural mesothelioma 2000–28
Model Mortality data Statistical model Hypothesis on birth cohort risks
1 1969–93 Age-cohort Assigned risks of birth cohorts after 1957 decline sharply from 0.44 to 0 in the next three birth cohorts
2 1969–98 Age-cohort Risks of birth cohorts after 1957 were assigned the risk of birth cohort 1953–57
3 1969–98 Age-cohort Risk of birth cohort 1958–62 was assigned 50% of the risk of birth cohort 1953–57 and birth cohorts
beyond 1962 were assigned zero risk
4 1969–98 Age-period-cohort Risk of birth cohort 1958–62 was assigned 50% of the risk of birth cohort 1953–57 and birth cohorts
beyond 1962 were assigned zero risk
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groups above 60 years, most notably for the eldest age groups.
On the other hand, among men and women younger than 60
years the age specific mortality rates were fairly constant dur-
ing the period 1969–98.
Table 2 evaluates the goodness of fit of different models for
men and women.Amongmen, age, cohort, and period all were
significant, but the introduction of age (change in deviance
8109; degrees of freedom (df) = 11) and cohort (change in
deviance 5000; df = 13) increased the fit considerably more
than period (change in deviance 627; df = 5). Two-factor
models fitted the data better than one-factor models and the
age-cohort model showed the best fit with least differences
between observed and fitted number of deaths. The introduc-
tion of a period effect in the age-cohort model was statistically
significant, especially for a period effect distinguishing 1996
onwards from 1995 backwards (change in deviance 24,
df = 1) Nonetheless, the overall results in terms of deviances
and degrees of freedomwere very similar when comparing the
age-cohort model and the age-period-cohort model. Among
women similar results were found, although a cohort-period
model had a better fit than an age-cohort model.
Table 3 presents the age specific mortality rates and the
relative risks for birth cohorts in model 3 for both men and
women. There was an exponential increase in the age specific
rates among men and women, reaching its peak in the age
group 80–84 years in both sexes. There was a steady increase
in the relative risk for the birth cohort 1888–92, reaching its
maximum for the birth cohort 1938–42 (relative risk 1.03, 95%
CI 0.82 to 1.29), and decreasing for birth cohorts after 1953. In
women, the birth cohort 1948–52 showed the highest relative
risk, but there was no specific trend over time.
Figures 3 and 4 present the predicted number of deaths
from pleural mesothelioma among men and women for 2000–
28. As reference, the observed mortality from pleural
mesothelioma in 1968–98 is included. The most plausible sce-
nario, model 3, predicted an increase in pleural mesothelioma
deaths from 333 cases in the year 2000 to a plateau of 490
cases in 2017, thereafter decreasing rapidly to 338 cases in
2028. The “old”model 1, based on mortality data from 1969 to
1993, predicted that the peak of annual deaths from pleural
mesothelioma will occur between 2025 and 2030, with over
950 deaths. For women, all models were fairly similar and pre-
dicted a continuous decrease from 33 cases in 2000 to 15 cases
in 2028.
Table 4 compares the peak number of deaths and total death
toll from pleural mesothelioma between 2000 and 2028
among the four distinguished models. The sensitivity analysis
showed that inclusion of an additional five years of mortality
data in the development of the age-cohort model has a large
impact on the predicted pleural mesothelioma mortality
among men. In reference to model 1, model 3 predicted a 49%
lower peak (470 cases) and a 44% lower total death toll (9649
Figure 1 Incidences (per 100 000 person-years) of deaths from
pleural mesothelioma among men, 1969–98, according to age
group and five-year period.
Table 2 Evaluation of goodness of fit (change in scaled deviance) of an
age-period-cohort modelling technique for number of deaths from pleural
mesothelioma, 1969–98
Terms in model
Reference for
significance
testing
Men Women
Scaled
deviance df p value
Scaled
deviance df p value
Intercept (1) – 9190 359 1397 359
Age (2) 1 1081 348 0.0000 338 348 0.0000
Cohort (3) 1 4190 346 0.0000 599 346 0.0000
Period (4) 1 8563 354 0.0000 1375 354 0.0007
Age + cohort (5) 2 335 335 0.0000 313 335 0.0211
Cohort + period (6) 3 1156 341 0.0000 350 341 0.0000
Age + period (7) 2 406 343 0.0000 318 343 0.0011
Age + period + cohort (8) 5 315 330 0.0013 301 330 0.0394
APC two-period, cut off 1996 (9) 5 311 334 0.0000 303 334 0.0012
Figure 2 Incidences (per 100 000 person-years) of deaths from
pleural mesothelioma among women, 1969–98, according to age
group and five-year period.
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cases). The assumptions on risks among birth cohort after
1953 were important, since model 2 predicted a 25% higher
peak and a 20% higher total death toll compared with model
3. The small differences betweenmodels 3 and 4 illustrated the
modest impact of the period effect in this modelling approach.
For women, the four models showed comparable results, with
model 4 predicting the smallest peak and total death toll.
DISCUSSION
The mortality of pleural mesothelioma in men has increased
from 65 cases in 1969 to 265 cases in 1998. The most plausible
prediction suggests that the number of deaths will rise to 490
in 2017 and subsequently decrease rapidly. The total death toll
between 2000 and 2082 is estimated to be over 12 000 cases.
For women, the number of deaths from pleural mesothelioma
will decrease from 33 cases in 2000 to 16 cases in 2028, with a
total death toll of approximately 800 cases. In contrast to pre-
vious studies which used shorter periods of observed
mortality, we predicted considerably fewer deaths and an ear-
lier time of the death peak.6 9 14 The sensitivity analysis showed
that assumptions in the age-cohort model may have a
profound effect on these predictions.
Table 3 Age specific mortality rates (per 100 000 person-years) and relative birth
cohort risks in an age-cohort model on observed mortality from pleural mesothelioma,
1969–98
Age group
Men Women
Age specific rate
per 100000
person-years 95% CI
Age specific rate
per 100000
person-years 95% CI
25–29 0.030 0.012 to 0.072 0.012 0.003 to 0.052
30–34 0.082 0.047 to 0.143 0.025 0.009 to 0.074
35–39 0.156 0.101 to 0.242 0.027 0.009 to 0.081
40–44 0.562 0.424 to 0.746 0.138 0.071 to 0.267
45–49 1.855 1.509 to 2.280 0.195 0.105 to 0.360
50–54 3.814 3.191 to 4.559 0.285 0.160 to 0.507
55–59 8.247 6.983 to 9.739 0.459 0.260 to 0.811
60–64 13.858 11.453 to 16.768 0.967 0.531 to 1.762
65–69 25.372 21.009 to 30.641 1.126 0.617 to 2.055
70–74 37.895 31.191 to 46.040 1.708 0.930 to 3.135
75–79 53.746 43.867 to 65.849 2.147 1.156 to 3.989
80–84 78.650 63.322 to 97.688 2.771 1.468 to 5.230
Cohort Risk 95% CI Risk 95% CI
1888–1892 0.01 0.28 0.02 to 4.71
1893–1897 0.09 0.05 to 0.16 0.72 0.24 to 2.12
1898–1902 0.13 0.09 to 0.19 0.68 0.30 to 1.52
1903–1907 0.15 0.11 to 0.20 0.70 0.34 to 1.43
1908–1912 0.26 0.21 to 0.33 1.05 0.54 to 2.03
1913–1917 0.31 0.25 to 0.39 0.82 0.43 to 1.58
1918–1922 0.41 0.33 to 0.50 1.11 0.59 to 2.07
1923–1927 0.49 0.40 to 0.59 1.08 0.58 to 2.02
1928–1932 0.67 0.55 to 0.82 1.43 0.77 to 2.66
1933–1937 0.78 0.64 to 0.95 1.19 0.64 to 2.20
1938–1942 1.03 0.82 to 1.29 1.43 0.69 to 2.94
1943–1947 1.00 1.00
1948–1952 0.99 0.74 to 1.32 1.50 0.65 to 3.46
1953–1957 0.67 0.45 to 0.99 0.37 0.12 to 1.18
Figure 3 Observed mortality from pleural mesothelioma among
men in 1969–98 and predicted number of deaths from pleural
mesothelioma among men for 2000–28, according to four
prediction models described in table 1.
Figure 4 Observed mortality from pleural mesothelioma among
women in 1969–98 and predicted number of deaths from pleural
mesothelioma among women for 2000–28, according to four
prediction models described in table 1.
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The presented predictions on future number of deaths from
pleural mesothelioma are strongly influenced by the assump-
tions behind the age-cohort model. A number of uncertainties
can be identified, primarily concerning the quality of the
available data for the predictions, choices in the statistical
modelling techniques, and expectations about future develop-
ments in nature and size of the population at risk.
The first source of uncertainty to be discussed is the quality
of the information on observed mortality from pleural
mesothelioma. In the Mortality Registry misclassification of
pleural mesothelioma cases as pleural cancer and vice versa is
inevitable to a certain extent.7 8 22 The large number of
unspecified mesothelioma deaths in 1996–98 were predomi-
nantly assigned to be of pleural origin. This was considered a
reasonable approach since more than 60% of cases of unspeci-
fied mesothelioma could be pleural and more than 90% of
pleural tumours were diagnosed as malignant pleural
mesothelioma in the cancer registry.15 This approach is limited
by unavailability of personal patient profiles, because of strict
regulations on data protection in the Netherlands. Hence, a
direct comparison between mortality and morbidity is not
possible. However, for the period 1989–98 the total number of
cases in the Cancer Registry and the Mortality Registry corre-
sponded very well.6 15 However, uncertainty remains in the
completeness of both registries. Although cancer registries
have been criticised recently for lack of completeness,23 it was
estimated that 95% of all cases are reported to the Cancer
Registry in the Netherlands and that pathological confirma-
tion of mesothelioma is about 90%.15
The strong increase in the male incidence rate of pleural
mesothelioma in the period 1969–98, may also be affected by
an increasing diagnostic awareness of mesothelioma over the
past 20 years.9 10 Although the extent of this effect cannot be
tested,15 the age specific rates were broadly proportional to the
difference of age minus age at first exposure raised to the
power 3.3, assuming an average age at first exposure of 25
years. This proportionality, together with the absence of a clear
increase among women, provides some evidence against a
strong impact of a diagnostic trend, as discussed elsewhere.10
A second source of uncertainty is the various choices made
in the statistical modelling procedures. The effects of specific
assumptions on the risk of birth cohorts after 1957 were
shown in the sensitivity analysis. Model 2 forecasted a 25%
higher peak and a 20% higher total death toll than model 3.
This was explained by the fact that birth cohort risks were
assumed to be constant at the risk of the birth cohort 1953–57.
Since in model 2 the birth cohort risks will not decrease over
time, the predicted mortality will level off at a plateau of over
600 deaths per year. It is suggested that this model is not a
reasonable scenario because of the strong decrease in asbestos
use after 1984 and a subsequent ban in 1993.12
However, uncertainty will remain for some time since the
risks of birth cohorts 1958–62 and beyond cannot be
estimated because of the small number of observed cases.
Since these birth cohort risks are unknown, future mortality
may vary between model 2 with a constant risk in birth
cohorts after 1957 (unlikely because of the asbestos ban in
1993) andmodel 3 with assumed zero risk after 1957 (unlikely
since not all asbestos exposure was eliminated in the
1980s).7–9 It is still too early to confirm whether asbestos con-
trol measures issued after 1977 have been effective. We agree
with other experts to await at least five years more for a better
appreciation of the change.8 9
The assumption of a constant pattern of age specific rates
over the projected period has been recognised as a crucial
premise on long term predictions.9 20 The effect of this
assumption was illustrated by comparing model 1 with model
3. The inclusion of the latest mortality data 1994–98 added a
substantial number of cases to model 3, especially among
older age groups. As a result model 3 estimated comparable
birth cohort risks to the previous model 1, but the age specific
rates in the older age groups decreased by 15–60%. It is
expected that the precision of the age specific rates in model 3
is higher than in model 1, primarily because of the larger
number of observed deaths. This result clearly illustrates that
these predictions go along with a high uncertainty. It will be of
interest whether updated projections for other Western Euro-
pean countries will reveal a similar spectacular decrease in
future mesothelioma deaths.24
The fit of the statistical models used calls for some caution
in interpreting the results of the predictions. The choice
between an age-cohort (AC) and age-period-cohort (APC)
model is difficult to make. From a statistical point of view it is
expected that an APC model would show a better fit, because
an additional parameter was included. The period effect in
model 4 may be the result of the introduction of the new codi-
fication ICD-10. Also, it may reflect the increasing awareness
in the Netherlands of the health risks of asbestos exposure
after the Stumphius study in 1969 and the first Guidance Note
P-116 on asbestos.13 The latter was originally aimed at the
asbestos industry and was issued to set personal protection
and technical safety measures when dealing with asbestos.
Alternatively, the period effect may reflect the calculation pro-
cedure used to obtain the pleural mesothelioma cases from the
cases coded C459 (unspecifiedmesothelioma).However,when
fitting other cut offs, such as 1993 or 1994, the goodness of fit
was very similar (data not shown). The sensitivity analysis
showed that the period effect used in APC model 4 differed
little from the ACmodel 3.When considering the use of an AC
model versus an APC model, we preferred the AC model
because it was simple and fitted well. Since the disease pattern
was reflected mostly by age and cohort effects rather than
period effects, the non-identifiability problem was also
avoided.19 The use of interaction terms has been studied
previously.19 25 While such extensions to an APC model are
theoretically possible, several authors do not recommend their
use,19 25 or propose them only for investigating the adequacy of
the assumption of common effects across the cohorts.19 Hence,
a prediction based on an AC model was chosen, which also
allows better comparison with results of other studies.6 8–10
A third source of uncertainty is the demographic develop-
ment of the general population in the Netherlands during the
period 2000–28. Future mortality is affected by population
growth, specifically by the ageing process. The overall popula-
tion in the Netherlands has increased about 25% in the past 30
years, with a clear shift towards the population older than 60
years. In the estimations of population growth in the Nether-
lands, the proportion of men over 65 years will increase from
10.4% in 2000 to 18.7% in 2028. For women a similar increase
is to be expected, albeit with a higher proportion already in
2000. Since the age specific mortality rates for pleural
mesothelioma are highest in the age groups over 65 years, the
Table 4 Comparison of peak numbers of deaths and
total death toll from pleural mesothelioma over
2000–28 according to four prediction models
described in table 1
Year of
peak
Peak death
number
Relative
deviation
Death toll
2000–28
Relative
deviation
Men
Model 1 2027 960 22061
Model 2 2028 613 −36.1% 14899 −32.5%
Model 3 2017 490 −49.0% 12412 −43.7%
Model 4 2017 501 −47.8% 12435 −43.6%
Women
Model 1 2007 37 861
Model 2 2007 36 −2.7% 893 3.7%
Model 3 2007 35 −5.4% 783 −9.1%
Model 4 2007 29 −21.6% 708 −17.7%
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expected shift towards older age will considerably increase the
predicted death toll. If demographics were to remain
unchanged in the next 30 years, the estimated peak in deaths
from pleural mesothelioma would appear slightly earlier and
would certainly be at least 20% lower.
Although the aforementioned sources of uncertainty apply
to both men and women, women have to be considered sepa-
rately. The age specific rates increased at much lower
magnitude than in men. There were few differences among
the four models and all models predicted a decrease in deaths
of women after 2007. In the Netherlands, women have been
far away from asbestos related activities and, thus, this is the
main plausible reason for the small number of cases among
women.6 However, it is unclear whether the occurrence of
pleural mesothelioma among women may partly reflect the
effects of environmentally related asbestos exposure.
In conclusion, the presented prediction updates the forecast
of pleural mesothelioma mortality from 2000 to 2028, taking
into account the latest available information on observed
mortality. The death toll is predicted to be 44% lower than
previously expected.6 9 The sensitivity analysis indicated that
the predictions were most influenced by differences in age
specific rates and, to a lesser extent, assumptions about the
birth cohort risks. The ageing process in society, initial asbes-
tos control measures, as well as changes of pleural mesothe-
lioma coding, may also play a role in the predictions. The
impact of these effects on the pleural mesothelioma mortality
will be revealed over time. It is advised to update the
predictions of mortality owing to pleural mesothelioma at
regular intervals in order to keep track of the uncertainties in
the current predictions.
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Main messages
• Mortality as a result of pleural mesothelioma in the Nether-
lands was predicted to be 44% lower than previously esti-
mated.
• The demographic shift towards older populations is
increasingly important for the incidence of pleural mesothe-
lioma.
• Predictions of future trends in mortality should be evaluated
with regard to sensitivity to assumptions and uncertainties in
the statistical modelling.
Policy implications
• The large number of asbestos related deaths to be expected
in the next 30 years warrants a stringent policy with regard
to asbestos exposure.
• It is advised to regularly update predictions of future trends
in pleural mesothelioma mortality as more mortality data
accrues.
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